Table 3.

Estimated annual clinical burden, including pneumococcal disease cases and deaths, attributable to the serotypes included in PCV10, PCV13, PCV15, and PCV20.

	PCV13 NIP Countries			PCV10 NIP Countries
	Argentina	Mexico	Chile	Colombia	Brazil
Population aged 0–4	3,668,251	10,047,365	1,166,146	4,373,565	12,704,860
IPD cases
PCV10 serotypes	66	68	7	36	120
PCV13 serotypes	112	682	55	371	1,537
PCV15 serotypes	122	682	67	371	1,598
PCV20 serotypes	171	957	81	385	1,876
Inpatient PNE cases
PCV10 serotypes	637	855	48	1,136	5,692
PCV13 serotypes	1,072	8,553	407	11,796	72,856
PCV15 serotypes	1,172	8,553	501	11,796	75,765
PCV20 serotypes	1,640	11,998	602	12,247	88,919
Outpatient PNE cases
PCV10 serotypes	238	6,843	2,170	4,443	6,040
PCV13 serotypes	401	68,428	18,241	46,124	77,312
PCV15 serotypes	438	68,428	22,427	46,124	80,400
PCV20 serotypes	613	95,986	26,975	47,888	94,359
OM cases
PCV10 serotypes	16,400	913	2,317	2,229	1,266
PCV13 serotypes	27,624	9,128	19,478	23,140	16,210
PCV15 serotypes	30,190	9,128	23,947	23,140	16,857
PCV20 serotypes	42,247	12,804	28,803	24,025	19,784
Total cases
PCV10 serotypes	17,341	8,679	4,543	7,843	13,118
PCV13 serotypes	29,209	86,791	38,181	81,431	167,915
PCV15 serotypes	31,922	86,791	46,942	81,431	174,620
PCV20 serotypes	44,671	121,745	56,461	84,545	204,938
Deaths
PCV10 serotypes	25	29	1	108	73
PCV13 serotypes	42	293	4	1,119	928
PCV15 serotypes	46	293	5	1,119	965
PCV20 serotypes	65	411	6	1,161	1,133

OM, otitis media; IPD, invasive pneumococcal disease; NIP, national immunization program; PCV, pneumococcal conjugate vaccine; PNE, pneumonia.